Retention rate and predictors of discontinuation for secukinumab treatment: real-life data in a cohort of patients with spondyloarthritis
Secukinumab demonstrates sustained effectiveness in SpA patients, with a significant proportion maintaining therapy over time. Retention is influenced by BMI, prior treatments, and disease phenotype, suggesting that outcomes may be optimised through tailored patient selection and early intervention.
Authors
- Mariele Gatto (ORCID: https://orcid.org/0000-0003-4012-1248)
- E. Marucco
- Valeria Data
- Claudia Lomater (ORCID: https://orcid.org/0000-0001-6512-941X)
- Annamaria Iagnocco (ORCID: https://orcid.org/0000-0001-5592-724X)
- Elisa Bellis (ORCID: https://orcid.org/0000-0002-9200-8215)
- Silvia Perrone
- G. Crepaldi
- Marta Saracco
Institutions
- University of Turin (IT)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2024-11-14
- DOI
- https://doi.org/10.55563/clinexprheumatol/cruuvo
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Celgene
- Celltrion
- Swedish Orphan Biovitrum
- Sanofi Genzyme